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Hemoglobin Concentration
in Acute Decompensated
Heart Failure
A Marker of Volume Status?*
Akshay S. Desai, MD, MPH
Boston, Massachusetts
Anemia is common in patients with chronic heart failure
across the spectrum of ejection fraction and is a powerful
predictor of rehospitalization rates and mortality (1–5).
Prevalence estimates vary widely according to heart failure
severity, ranging from 10% in those with mild symptoms
to50% in those with advanced disease (6). The etiology of
eart failure–associated anemia is undoubtedly multifacto-
ial, with posited contributions from the dilutional effects of
olume overload, comorbid renal dysfunction and impaired
rythropoietin production, iron deficiency, inflammation/
ytokine activation, malnutrition, and drug therapy (e.g.,
spirin, angiotensin-converting enzyme inhibitors) (7). In-
ependent of the specific cause, a 1% decline in hematocrit
as been linearly associated with a 3% increase in the risk of
eath (3,5) Changes in hemoglobin concentration over time
dd prognostic information, with higher cardiovascular risk
ssociated with persistent, incident, or worsening anemia
ver serial observation in ambulatory heart failure popula-
ions (4,8).
See page 1973
Although nearly half of patients hospitalized with acute
decompensated heart failure (ADHF) are anemic (9), the
prognostic importance of hemoglobin concentration in this
setting is less clear. Data from large registries and random-
ized controlled trials have returned mixed results, with
anemia variably associated with short-term, but not long-
term, mortality after adjustment for key confounders such as
age, gender, and renal function (9–13). Because most heart
failure admissions are related to congestive exacerbations as
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findings in the studies of acute and chronic heart failure may
reflect the greater relative contribution of transient hemodi-
lution to anemia in the setting of heart failure decompen-
sation. There are some circumstantial data to suggest this is
true; the prevalence of anemia in studies of hospitalized
heart failure patients exceeds that in the ambulatory setting,
and plasma volume is known to be expanded in relation to
heart failure severity (14). As well, rising hemoglobin, or
hemoconcentration, during decongestive treatment of acute
heart failure decompensation has been associated with
improved clinical outcomes (15,16).
In this issue of the Journal, van der Meer et al. (17)
present important new information regarding the prognos-
tic relevance of anemia and changing hemoglobin concen-
tration during treatment for acute heart failure. Using a
subset of 1,969 patients with acute heart failure, mild-
moderate renal dysfunction, and serial hemoglobin mea-
surements available over 7 days enrolled in the PROTECT
(Placebo-Controlled Randomized Study of Selective Aden-
osine A1 Receptor Antagonist Rolofylline for Patients
Hospitalized with Acute Decompensated Heart Failure and
Volume Overload to Assess Treatment Effect on Conges-
tion and Renal Function) study, they examined the
association between anemia, hemoconcentration, and
mortality at 180 days. Several key findings are notable:
similar to previous studies of ADHF, anemia as defined by
the World Health Organization criteria (13 g/dl for men,
12 g/dl for women) was present at baseline in 50.3% of
subjects. During the first week of hospital treatment for
heart failure, hemoglobin increased in 69.1% of subjects
with an average rise of 0.3  0.7 g/dl. Hemoconcentration
was associated with higher serum albumin, greater weight
loss, and less residual congestion at day 7 (41.1% vs. 53.2%,
p  0.01), but also with worsening renal function. Despite
the rise in serum creatinine with treatment, subjects with
hemoconcentration experienced lower rates of all-cause
mortality at 180 days than those without hemoconcentra-
tion. In multivariable analyses adjusted for age and renal
function, the absolute change in hemoglobin, but not
baseline hemoglobin, was associated with the risk for death
(hazard ratio: 0.66; 95% confidence interval: 0.51 to 0.86; p
 0.002).
Whether defined by filling pressures, physical examina-
tion findings, natriuretic peptide levels, or direct measure-
ment of blood volume, volume overload is a powerful
marker of risk in heart failure (18–20). Conversely, effective
decongestion during acute heart failure decompensation is
associated with improved clinical outcomes (21–23). Al-
though patients with hemoconcentration received a lower
total dose of diuretics in this study, the associated albumin
rise, weight loss, and improvement in clinical signs of
congestion suggests they experienced more effective reduc-
tion in intravascular plasma volume with treatment. Acute
hemoglobin changes during hemodialysis have long been
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analogy, rising hemoglobin over a longer time interval in the
hospitalized heart failure patient may be a subtle marker of
diuretic response. In this context, the observed association
between hemoconcentration and improved clinical out-
comes may in part reflect the results of more effective heart
failure treatment. It is notable that patients with rising
hemoglobin experienced better outcomes despite a slight
rise in serum creatinine. In this way, these findings
extend the results of other recent analyses emphasizing
that resolution of congestion may be important even
when it occurs at the expense of some deterioration in
renal function. (15,24).
If hemoconcentration is a marker of effective volume
removal with heart failure therapy and better outcomes, the
failure to hemoconcentrate could be an ominous sign.
Beyond changes in plasma volume, however, hemoglobin
concentration during hospitalization may be affected by a
number of other factors, including subclinical bleeding,
medications, nutritional status, and serial phlebotomy for
laboratory measurements. Although patients with severe
anemia (hemoglobin 8 g/dl) or the need for transfusion
were systematically excluded from the PROTECT study,
those with less dramatic or subclinical bleeding may have
been randomized. Accordingly, lack of hemoconcentration
may not consistently reflect residual volume overload, and
these data do not support routine intensification of diuretic
therapy for patients in whom the hemoglobin fails to rise.
Moreover, it is not clear from this analysis that all patients
with hemoconcentration have reached a therapeutic limit or
are completely dry. Because the rate of hemoglobin rise
appears to be correlated with the rate of weight loss, rising
hemoglobin may simply be a marker that the rate of intravas-
cular volume depletion has exceeded the plasma refill rate from
the interstitium. For patients with residual congestion by other
measures, ongoing diuresis, perhaps at a slower rate, may be
appropriate despite hemoconcentration.
As the investigators acknowledge, these data reflect the
results of a post hoc analysis in a selected population with
acute heart failure, renal dysfunction, and predominantly
low ejection fraction from a randomized clinical trial. As
with other subgroup analyses, the results are vulnerable to
confounding and may not be easily generalized to the
broader population with ADHF. Nonetheless, these obser-
vations expand the available literature regarding the prog-
nostic implications of hemoglobin concentration in the
acute heart failure setting. The lack of association between
baseline anemia and mortality contrasts with prior studies in
acute heart failure examining in-hospital or near-term
mortality (9–11), but is consistent with the results of studies
examining outcomes over a longer time horizon (12,13).
Although better outcomes in those with hemoconcentration
may in part be related to lesser severity of heart failure at
baseline (suggested by the slightly better baseline renal
function and lower diuretic requirement during hospitaliza-
tion), similar results from the work of Testani et al. (15) inthe ESCAPE (Evaluation Study of Congestive Heart Fail-
ure and Pulmonary Artery Catheterization Effectiveness)
trial suggest that this may be a robust finding. If so, taken
together, these data support an important role for hemodi-
lution as a significant contributor to anemia in patients with
ADHF.
There is a need for considerable additional information
before these findings could be used to guide clinical practice.
The optimal time to assess hemoconcentration remains
uncertain, because there is considerable variability in the
diuretic response and the plasma refill rate from the ex-
travascular space. The 7-day interval used in this analysis
was arbitrarily selected based on the data that were available
within the PROTECT study, and it is not clear whether
assessment at a different time point (e.g., hospital discharge)
would provide more relevant information. The optimal
hemoglobin target for a given patient is uncertain, as it is
difficult to quantify excess plasma volume without special-
ized technology; there is little guidance here about how
much hemoconcentration is beneficial and whether there is
a point of diminishing returns with continued rise in
hemoglobin. It is notable that treatment guided by other
indirect markers of volume status (natriuretic peptides,
intrathoracic impedance) has in general not improved out-
comes over care guided by the routine clinical assessment
(25,26). Whether direct measurement of blood volume
using novel radiolabeled dye dilution techniques will help
direct more effective heart failure therapy is being tested
in the ongoing TEAM-HF (Treating to Euvolemia by
Clinical Assessment and Measured Blood Volume in Heart
Failure) trial (27).
In an era of increasing concern about rehospitalization
and mortality following hospitalization for ADHF, addi-
tional levers to facilitate optimal in-hospital treatment are
clearly needed. Although a number of questions remain,
these data from van der Meer et al. provide support for the
notion that anemia in the acute heart failure population may
in part reflect the severity of volume overload. Hemocon-
centration may follow on the effective relief of congestion
and mark patients with a better prognosis. The association
between hemoconcentration, but not baseline anemia, and
prognosis seen here may be attributable to the dominant
impact of effective decongestion on clinical outcomes. These
data provide reassuring support for current guidelines rec-
ommending use of diuretics to restore normal volume status
in patients with ADHF prior to discharge (28) and high-
light that serial hemoglobin changes may be a useful adjunct
to the standard clinical assessment in evaluating the re-
sponse to therapy.
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